Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLSTAR
jRCT2031210653Phase 3Active, not recruiting
- Sponsor
- Nihon Servier
- Start
- Apr 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in metastatic colorectal adenocarcinoma (mCRC) and colorectal adenocarcinoma comparing Futuximab/modotuximab + trifluridine/tipiracil with Trifluridine/tipiracil (2 arms). Primary endpoints: Incidence of dose-limiting toxicities and Overall survival. Started Apr 2022; status: active, not recruiting.
02
Drugs
futuximab + modotuximabtrifluridine + tipiracil
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on jRCT2031210653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210653.